Predicine to Present Six Studies, including the Demonstration of the Clinical Utility of Its PredicineBEACON™, a Tissue-agnostic MRD Liquid Biopsy Solution, in Genitourinary (GU) Cancers at 2022 ASCO-GU Annual Conference PredicineBEACON™ platform offers next-generation, tissue-agnostic MRD detection, leveraging blood, urine- and/or tissue-based comprehensive genomic profiling solutions in solid tumors including bladder, prostate, and renal tumors...

Predicine Appoints Clint Webb as New General Counsel to Support Its International Expansion SILICON VALLEY, Calif., Jan. 19, 2022 /PRNewswire/ — Predicine, a global molecular insights company, announced today that it has appointed Clint Webb as its new General Counsel (GC). This is the most recent of several executive appointments aimed at supporting Predicine’s international expansion and further developing its industry-leading liquid...

Predicine Appoints Dr. Dennis Merkle as New Chief Executive Officer SILICON VALLEY, Calif., Jan. 4, 2022 /PRNewswire/ — Predicine, a global molecular insights company, announced today that it has appointed Dennis Merkle, PhD, MBA, as its new Chief Executive Officer (CEO) for Predicine Europe as well as its Global Head of Biopharma Business. Dr. Merkle moves into the...

Predicine Appoints Linh H. Le as New Chief Financial Officer SILICON VALLEY, Calif., December 21, 2021 – Predicine Corporation, a global molecular insights company, announced today the appointment of Linh H. Le as its new Chief Financial Officer (CFO). Le brings decades of healthcare experience as a seasoned executive in medical device and clinical genetic...

Event October 22, 2021 Predicine CEO Dr. Shidong Jia will be presenting, along with academic and biopharma collaborators, on the liquid biopsy solutions provided by Predicine. Register for the Symposium (HERE)    

Predicine presented data highlighting the use of PredicineCARE and PredicineATLAS in patients with metastatic breast cancer and early stage bladder cancer. Publications can be found below: (Breast Cancer Abstract) (Bladder Cancer Abstract)    

Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer. The publications can be found online at: (HERE)

Results from the studies utilizing Predicine’s blood-based liquid biopsy assay to detect copy number loss in PTEN, RB1, TP53, etc. are now published in Frontiers in Oncology and JCO Precision Oncology, respectively. Predicine, Inc. announced today results from two liquid biopsy studies demonstrating the technical capability and clinical application of the PredicineCARE™ liquid biopsy NGS...

Results from the study using liquid biopsy to detect copy number variations (CNVs), especially PTEN copy number loss, are now published in JCO Precision Oncology. Predicine, Inc. today announced results from a prostate cancer liquid biopsy study evaluating the landscape of genomic alterations in 231 patients with metastatic castration-resistant prostate cancer (mCRPC) from US and...

Data presentations to show clinical utility of Predicine’s urine- and blood-based liquid biopsy solutions for precision cancer care and clinical drug development. Predicine announced today that new liquid biopsy data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancer Symposium, taking place from February 11-13, 2021. Among featured highlights are...